The United Kingdom and the United States have secured a landmark bilateral deal that will maintain no tariffs on UK drug shipments being sold in the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise expenditure on medicines through the National Health Service (NHS). This pledge guarantees that duties on these vital exports will remain at zero for a duration of 36 months.
This agreement comes after earlier threats to hike duties on patented drug products, with potential rates floated up to one hundred percent.
"This agreement between the UK bolsters the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to U.S.–U.K. medicine commerce," a statement said.
Trade Importance
Pharmaceuticals represent one of the Britain's largest goods shipped to the US, which is by far the largest buyer for major British pharmaceutical firms.
Export figures reveal that in the one-year period leading up to last September, the UK sold medicines totaling billions to the US. This amount represented 17.4% of total UK exports in that span.
"This agreement secures employment, increases investment and paves the way for the UK to become a international leader for medical research," a minister stated.
Key NHS Changes
The deal includes several notable pledges from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a target to increase total health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Previously, repayments were more than twenty percent.
Recent Tensions
The pact takes place against a ongoing dispute between the drug companies and the ministers over spending levels and regulatory access.
These tensions were exacerbated by claims that US customers were charged significantly more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar investments have been pledged toward American operations.
A senior figure publicly accepted that the NHS must spend more on medicines, noting that its spending on drugs had decreased as a proportion of its total funding over the last ten years.
